We Give Shareholders a Voice

TherapeuticsMD, Inc. (TXMD) Information Request Form

Levi & Korsinsky, LLP announces the expansion of the class period of a complaint in the USDC for the Southern District of Florida on behalf of shareholders of TherapeuticsMD, Inc. (NYSEMKT: TXMD) who purchased shares between July 7, 2016 and May 7, 2017.

The complaint alleges that, throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company’s stock to trade at artificially inflated prices. In particular, the complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.

On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.

If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving TherapeuticsMD, Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other TherapeuticsMD, Inc. shareholders.

Sincerely,

Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear